<span item_type="fundamental" item_id="a639118fbfff752d5355f48746b5bbe6" counter_id="ST/US/NAKA" env="prod"></span><span item_type="announcement" item_id="523546191488747521" env="prod"></span><p>Revenue: As of FY2024 Q2, the actual value is USD 639.06 K.</p><p>EPS: As of FY2024 Q2, the actual value is USD -0.26.</p><p>EBIT: As of FY2024 Q2, the actual value is USD -1.037 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Patient Care Services</strong>: Revenue for the three months ended June 30, 2024, was $608,925, a decrease from $891,350 in the same period in 2023. For the six months ended June 30, 2024, revenue was $1,394,768, down from $1,959,305 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1946573/000149315224031760/form10-q.htm"></span></li><li><strong>Product Retail Sales</strong>: Revenue for the three months ended June 30, 2024, was $30,132, a decrease from $88,188 in the same period in 2023. For the six months ended June 30, 2024, revenue was $73,318, down from $180,578 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1946573/000149315224031760/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended June 30, 2024, the net loss was - $1,319,653, compared to - $596,408 for the same period in 2023. For the six months ended June 30, 2024, the net loss was - $1,601,979, compared to - $777,387 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1946573/000149315224031760/form10-q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the three months ended June 30, 2024, were $1,676,250, an increase from $1,580,827 in 2023. For the six months ended June 30, 2024, operating expenses were $2,742,406, a decrease from $2,946,377 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1946573/000149315224031760/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities for the six months ended June 30, 2024, was - $1,126,976, compared to - $274,964 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1946573/000149315224031760/form10-q.htm"></span></li><li><strong>Free Cash Flow</strong>: Not explicitly stated, but net cash provided by financing activities was $5,352,664 for the six months ended June 30, 2024, compared to $213,091 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1946573/000149315224031760/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Insurance Reimbursements</strong>: The company earned $91,553 in reimbursements from insurance payers during the three months ending June 30, 2024, a 163.7% increase over the $34,722 earned for the three months ending March 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1946573/000149315224031760/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue shifting towards insurance billing with commercial and governmental payers, including Medicare and Medicaid, to optimize revenue and improve margins.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1946573/000149315224031760/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: No specific plans related to divestitures or emerging segments were mentioned in the report.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1946573/000149315224031760/form10-q.htm"></span></li></ul>

Kindly MD | 10-Q: FY2024 Q2 Revenue: USD 639.06 K